Nuvectis Pharma (NASDAQ: NVCT) sets at-the-market share sales via Jefferies
Rhea-AI Filing Summary
Nuvectis Pharma, Inc. (NVCT) established a new “at the market” equity offering program by entering into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026. Under this arrangement, Nuvectis may sell shares of its common stock from time to time through Jefferies as sales agent, in transactions deemed an “at the market offering” under Rule 415(a)(4). The program is supported by a new Form S-3 shelf registration statement registering $200 million in securities, for which a prospectus supplement is expected to be filed on August 21, 2026.
Jefferies will use commercially reasonable efforts to place shares but is not obligated to sell any specific amount, and there is no escrow or similar arrangement for proceeds. Nuvectis will pay Jefferies up to 3.0% of the gross proceeds from any shares sold and reimburse certain costs, while providing customary indemnification. On July 20, 2026, Nuvectis terminated its prior at-the-market offering program and related prospectus supplement; no further sales will occur under that prior program.
Positive
- None.
Negative
- None.
Filing Explained
The disclosure creates an at-the-market capacity, not a completed financing: it does not report shares sold, proceeds received, or resulting dilution, so any ownership impact remains conditional on later sales.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shelf registration capacity: $200 million in securities
Sales agent commission: Up to 3.0% of gross proceeds
Sale Agreement date: August 21, 2026
+1 more
4 metrics
Shelf registration capacity
$200 million in securities
Registered under a new Form S-3 shelf filed on August 21, 2026
Sales agent commission
Up to 3.0% of gross proceeds
Compensation to Jefferies for ATM Shares sold under the Open Market Sale Agreement
Sale Agreement date
August 21, 2026
Date Nuvectis entered into the Open Market Sale Agreement with Jefferies
Termination of prior ATM
July 20, 2026
Date Nuvectis terminated its prior at-the-market offering program
Key Terms
at the market offering, Registration Statement on Form S-3, Open Market Sale Agreement, prospectus supplement, +1 more
5 terms
at the market offering financial
"Sales of the ATM Shares, if any, will be made in sales deemed to be an “at the market offering”"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
Registration Statement on Form S-3 regulatory
"under a new shelf Registration Statement on Form S-3 registering $200 million in securities"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
Open Market Sale Agreement financial
"entered into an Open Market Sale (the “Sale Agreement”) with Jefferies LLC"
A contract that lets a shareholder or issuer authorize a broker to sell stock into the public market over time rather than to one specific buyer. Think of it like hiring a salesperson to quietly sell items from your garage in small batches so you don’t crash the price; for investors it matters because it increases supply and liquidity, can put downward pressure on the share price, and signals an upcoming flow of shares into the market.
prospectus supplement regulatory
"expects to file a prospectus supplement (the “Prospectus Supplement”), relating to the Sale Agreement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Offering Details
ATM
Offering
Offering Type
ATM
FAQ
What did Nuvectis Pharma (NVCT) announce regarding a new at-the-market offering program?
Nuvectis Pharma entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026, allowing the company to sell common stock from time to time through Jefferies in an “at the market offering” under Rule 415(a)(4), subject to a new Form S-3 shelf registration.
What is the size of Nuvectis Pharma’s new shelf registration mentioned for NVCT?
The new shelf Registration Statement on Form S-3 registers $200 million in securities. A related prospectus supplement for the at-the-market program with Jefferies LLC is expected to be filed on August 21, 2026.
How is Jefferies LLC compensated in Nuvectis Pharma’s NVCT at-the-market program?
Jefferies LLC will receive up to 3.0% of the gross proceeds from sales of Nuvectis Pharma’s common stock under the at-the-market program. Nuvectis has also agreed to pay certain costs and expenses and to provide customary indemnification to Jefferies.
Did Nuvectis Pharma (NVCT) terminate any prior at-the-market offering program?
Yes. On July 20, 2026, Nuvectis Pharma terminated its prior at-the-market offering program conducted under a prospectus supplement filed February 13, 2026, tied to Registration Statement on Form S-3 (File No. 333-293459). No further sales will be made under that prior program.
Will proceeds from the NVCT at-the-market offering be held in escrow or a similar structure?
No. The disclosure states that there is no arrangement for funds to be received in any escrow, trust, or similar arrangement in connection with sales of Nuvectis Pharma’s common stock under the at-the-market program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
